COST Action CA20121

Bench to Bedside transition for Pharmacological regulation of NRF2 in non communicable diseases

About

Non-communicable diseases (NCDs) account for 77% of all deaths in Europe and remain the most prevalent and without effective therapy. Networking among multidisciplinary teams that explore disease from a perspective of causative pathomechanisms rather than clinical symptoms is the most appropriate approach to overcome this problem.

The transcription factor NRF2 is a master regulator of multiple cytoprotective responses and a key molecular link among many NCDs. It provides a unique strategy for drug development and repurposing that is now starting to be translated to the pharmacological and clinical arena.

Objetive

The main aim and objective of the Action CA20121 is to share basic, pharmacological, and clinical knowledge about transcription factor NRF2, master regulator of multiple cytoprotective functions, and to integrate it into the stream of EU social, clinical and economic sectors with capacity to translate this knowledge into innovative therapeutics for several non-communicable diseases.

The Challenge

The main aim and objective of the Action CA20121 is to share basic, pharmacological, and clinical knowledge about transcription factor NRF2, master regulator of multiple cytoprotective functions, and to integrate it into the stream of EU social, clinical and economic sectors with capacity to translate this knowledge into innovative therapeutics for several non-communicable diseases.

Latest news